Pathology & Understanding Your Astrocytoma Report

Your pathology report is the “source of truth” for your diagnosis. It is a technical document that combines what the pathologist saw under a microscope (histology) with the genetic tests performed on the tumor tissue (molecular diagnostics) ^[1][2]. Under current guidelines, the molecular findings are often more important than the visual ones.

The Grading System (2, 3, or 4)

The World Health Organization (WHO) grades astrocytomas on a scale of 2 to 4. While Grade 2 is considered the least aggressive and Grade 4 the most, these numbers are now determined by both how the cells look and their genetic makeup ^[3].

• Grade 2: The cells grow slowly and look relatively similar to healthy astrocytes ^[4].
• Grade 3: The cells show more “anaplasia” (abnormal appearance) and a higher mitotic rate (they are dividing more quickly) ^[3].
• Grade 4: This is the most aggressive grade. Historically, it was diagnosed if the pathologist saw necrosis (cell death) or microvascular proliferation (new, abnormal blood vessel growth) ^[5].

The “Grade 4” Exception: Today, even if a tumor looks like a Grade 2 or 3 under the microscope, it is automatically classified as Grade 4 if it has a specific genetic change called CDKN2A/B homozygous deletion ^[5][4]. This marker is a powerful indicator that the tumor may behave more aggressively, regardless of its physical appearance ^[3][6].

MGMT Promoter Methylation: Predicting Treatment Response

One of the most important terms on your report for treatment planning is MGMT promoter methylation.

• Methylated: This is generally a positive finding. It means the tumor’s “repair kit” (the MGMT gene) is turned off, making the tumor more vulnerable to chemotherapy drugs like temozolomide (TMZ) ^[7][8].
• Unmethylated: The tumor can repair the damage from chemotherapy more easily. However, for IDH-mutant astrocytomas, chemotherapy is generally still part of the standard treatment plan regardless of MGMT status. Your doctor will use this information to set realistic expectations and may choose alternative drugs to ensure you get the most effective care ^[9][10].

Advanced Testing Methods

If any of these markers are missing, ask your doctor if further testing is needed. You may hear terms like Next-Generation Sequencing (NGS) (a broad genetic scan), FISH (a test that maps specific chromosome changes using fluorescent probes), or IHC (a stain that highlights specific proteins under a microscope). These advanced tests complete the molecular picture ^[11][12].

Pathology Report Completeness Checklist

A modern, complete pathology report for an adult astrocytoma should include these specific items to ensure an accurate diagnosis under current 2021 standards ^[1][2]:

• [ ] IDH Mutation Status: Must be IDH-mutant (usually IDH1 or IDH2) ^[13].
• [ ] 1p/19q Codeletion Status: Must be negative (non-codeleted) to confirm it is an astrocytoma, not an oligodendroglioma ^[1].
• [ ] ATRX Status: Usually shows “loss of expression” or a mutation ^[14].
• [ ] TP53 Status: Often shows a mutation ^[14].
• [ ] CDKN2A/B Status: Specifically looking for “homozygous deletion” ^[5].
• [ ] MGMT Promoter Status: Reported as methylated or unmethylated ^[7].
• [ ] Histological Features: Notes on mitotic activity, necrosis, or blood vessel changes ^[3].